Starting Treatment With Agonist Replacement Therapies Follow-up Study

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yih-Ing Hser, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT01592461
First received: May 3, 2012
Last updated: August 4, 2016
Last verified: August 2016

May 3, 2012
August 4, 2016
September 2010
August 2016   (final data collection date for primary outcome measure)
Opioid use as determined by the Timeline Follow Back measure [ Time Frame: from 2006-2009 to 2011-2016 ] [ Designated as safety issue: No ]
Opiate use over approximately ten years time period
Not Provided
Complete list of historical versions of study NCT01592461 on ClinicalTrials.gov Archive Site
mortality [ Time Frame: from 2006-2009 to 2011-2016 ] [ Designated as safety issue: No ]
Rate of mortality over approximately ten years time period
Not Provided
Not Provided
Not Provided
 
Starting Treatment With Agonist Replacement Therapies Follow-up Study
START Follow-up Study (NIDA CTN Protocol 0050)

The purpose of the study is to conduct a follow-up of substance abuse patients (n=1,269) about 2 to 5 years since they were originally recruited from 8 substance abuse treatment clinics (located in 5 states) to participate in a prior clinical trial study called "START" (Starting Treatment with Agonist Replacement Therapies). The START Follow-up Study will be conducted over 5 years and will involve three follow-up interviews with START participants.

The specific aims of the START Follow-up Study are as follows.

  1. To determine longer-term outcomes of Suboxone versus methadone treatment received in the START
  2. To investigate patient and treatment factors associated with post-START treatment access, utilization, and outcomes among Suboxone and methadone patients
  3. To explore other correlates of the long-term outcomes among START patients.

The primary outcome is the trajectory of opioid use since START entry, operationalized as number of days using opioids per month over the follow-up period since START enrollment. Other long-term outcomes of interest will include alcohol and other drug use, mental and physical health, quality of life, criminal justice status, HIV/HCV risk behaviors, and mortality. Treatment access and utilization factors of interest will include: predisposing personal factors, treatment experiences, and perceptions and attitudes toward treatment. Other correlates of interest will include cognitive functioning, mental health functioning, and social support.

2.2 Hypotheses There will be no differences in long-term outcomes of participants randomized to Suboxone treatment versus methadone treatment. To assess this outcome, trajectories of opioid use (operationalized as number of days using opioids per month over the follow-up period since START enrollment) will be analyzed. Other secondary long-term outcomes of interest will also be analyzed and will include alcohol and other drug use, mental and physical health, quality of life, criminal justice status, HIV/HCV risk behaviors, and mortality. Participants with greater access and utilization of treatment, fewer predisposing personal factors, greater social support, and more positive perceptions and attitudes toward treatment, will be more likely to be a member of the low or decreasing drug use trajectories.

2.3 Study Design This longitudinal, observational study will involve contacting the study participants from the original START study for future assessments. The study is expected to be completed in five years.

The follow-up study will consist of three interviews of the START study participants, beginning approximately 2 to 5 years after initial enrollment in the START study and will assess these participants over a 5-year period to provide long-term outcome data 7 to 10 years after START enrollment. This study information will be supplemented by (electronic) medical and other administrative records, as available. An intent-to-treat design will be adopted to include all 1,269 study participants enrolled in START.

Figure 1 presents a summary of the timeline for the conduct of project activities. There will be three participant interviews over the five years of the project. After receiving IRB approval for the conduct of the study, the START community treatment provider (CTP) or Node staff will contact their START participants, obtain participant consent to take part in the follow-up study, and conduct the initial assessment. This assessment will take place in the clinic if possible and by phone if the participant is not able to come in person.

By agreeing to take part in this study the participant will agree to:

  1. Updating their locator information initially and throughout the duration of the study;
  2. Sharing of clinic and survey data with the lead research team (UCLA);
  3. Completing various assessments and providing urine and oral fluid/blood specimens for lab assessments;
  4. Providing access to administrative records (e.g., medical records, criminal justice records);
  5. Being contacted by the study staff for 2 more interviews in person or by phone (consented prior to each interview).

Local CTP or Node staff will conduct the Visit 1 interview in Years 1-2 of the START follow-up study. Enrollment for the Visit 1 interview will remain open for the life of the study to allow sites that are able to continue to seek participants for Visit 1 beyond Year 2 of the study to do so. The Lead Node staff will conduct the Visit 2 interview by telephone approximately 12 months after the completion of Visit 1. The Lead Node and/or CTP staff will conduct another participant interview approximately 12-18 months after Visit 2 is completed. If a study participant is found late in the study progress for Visit 1, the following visits, 2 and 3 will occur sooner than originally planned, but as far apart as possible. All assessments are completed by the end of Year 5 of the START follow-up study.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Participants will include the 1,269 study participants from the original START Study (CTN-0027) that was conducted from 2006 to 2010 at eight community treatment programs (CTPs).
Opioid Dependence
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
877
August 2016
August 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • To be eligible to participate in the study, individuals must have participated in CTN-0027 START.
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01592461
CTN-0050, U10DA013045
No
Yes
Deidentified data will be shared via NIDA Clinical Trials Network Website
Yih-Ing Hser, University of California, Los Angeles
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Principal Investigator: Yih-Ing Hser, Ph.D. University of California, Los Angeles
University of California, Los Angeles
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP